Company ProfilePremium

Nyrada Inc.

Company Profile Analysis

Ticker: NYR.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nyrada Inc. - Company showcase

Year Founded & Workforce

2017

Nyrada Inc. logo

Nyrada Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nyrada Inc. Overview

Nyrada is a single-asset, clinical-stage Australian biotechnology company, incorporated in Delaware. Its platform is the inhibition of Transient Receptor Potential Canonical (TRPC) 3/6/7 ion channels. Its lead molecule, Xolatryp®, is a first-in-class intravenous small molecule designed to limit pathological calcium influx into cells exposed to ischaemic or toxic stress. Xolatryp completed a 48-subject Phase I trial in healthy volunteers in 2025 with no serious adverse events. In July 2026 it entered PROTECT-MI, a 100-patient, randomised, placebo-controlled Phase IIa trial in STEMI heart-attack patients undergoing primary PCI. No approved therapy exists for myocardial ischaemia-reperfusion injury. Preclinical data also support use in ischaemic stroke, traumatic brain injury and anthracycline (doxorubicin) cardiotoxicity, plus possible anti-tumour additivity. Nyrada has no product revenue and funds itself through equity and Australia's refundable R&D tax incentive. A A$12m placement in September 2026 is intended to fund PROTECT-MI to topline data, expected in 2H CY2027.


Company's own description

Nyrada describes itself as a clinical-stage biotechnology company focused on discovering and developing innovative small-molecule therapies that target TRPC ion channels. It states that its lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection and oncology models, has completed a first-in-human Phase I trial, and is now in a Phase IIa trial assessing safety and preliminary efficacy in reducing cardiac reperfusion injury in STEMI patients undergoing PCI (FY2026 Full Year Results, 18 Aug 2026).

The FY2023 Annual Report gave the strategic framing that still applies. The vision was to become a high-growth pharmaceutical discovery and development company specialising in early-stage development of novel treatments. The strategy was to target diseases with unmet clinical need or suboptimal current treatments, and to monetise them by advancing highly optimised drug candidates.

Independent characterisation

Nyrada is a pre-revenue, single-mechanism, single-lead-asset drug developer. Its business model is "develop-to-partner." At IPO in 2020, CEO James Bonnar described the plan as taking drug candidates up to about Phase IIa and then selling or licensing them (Small Caps, Feb 2020). The FY2026 materials and the September 2026 raise are consistent with that plan: they prioritise a clean Phase IIa readout, a US FDA IND, a commercial dose form, and a follow-on oral TRPC inhibitor. These are the assets a pharmaceutical licensee would want to see.

Revenue model

Revenue typeStatusComment
Product sales—No approved products
Services——
Subscription——
Licensing / milestonesNone to dateIntended future model: out-license or sale after Phase IIa
"Other income"RecurringMainly the Australian refundable R&D tax incentive, plus interest income. Reported "revenue" of A$2.56m in FY2025 was of this nature.

Value-chain position

Nyrada covers discovery and preclinical pharmacology through early clinical development (Phase I–IIa). Medicinal chemistry, GLP toxicology, drug manufacturing (CMC), clinical operations and preclinical efficacy studies are outsourced to contract research and manufacturing organisations and academic collaborators. The specific CROs and CDMOs are not publicly named in the sources reviewed. Commercial manufacturing, late-stage trials and commercialisation would fall to a future partner.

Customer types and end-markets

There are no current customers. The prospective customers are large and mid-cap pharmaceutical companies with interests in acute cardiology, cardio-oncology, critical care or neurology. Ultimately, the drug would be prescribed in hospitals:

  • Interventional cardiology: STEMI patients undergoing primary PCI

  • Cardio-oncology: patients receiving anthracycline chemotherapy such as doxorubicin

  • Acute neurology: ischaemic stroke and traumatic brain injury

  • Possible extension to oncology combination therapy (preclinical anti-tumour additivity with doxorubicin)

Strategy

Stated strategy (themes from FY2026 results and the Sept 2026 raise)

  • FY2026 was described as "transformational": the company completed first-in-human work and moved into patient testing.

  • FY2027 priorities: (1) advance PROTECT-MI to conclusion and data readout; (2) lodge an IND with the US FDA; (3) move other preclinical programs toward the clinic to enhance Xolatryp's value.

  • Sept 2026 capital-raise priorities, per the CEO: complete Phase IIa, broaden the pipeline, develop an oral TRPC asset, and develop a commercial dose form of Xolatryp.

Initiatives announced in the last 24 months

InitiativeTimingDetailStatus
Phase I first-in-human trialFeb–Aug 202548 healthy volunteers, staged cohortsCompleted; positive
PROTECT-MI Phase IIaHREC Jan 2026; first patient Jul 2026Randomised, double-blind, placebo-controlled; 100 evaluable patients, 1:1; primary endpoint safety and tolerability; secondary endpoints infarct extent, cardiac function, troponin I and arrhythmiasRecruiting; topline Q3/Q4 CY2027
US FDA INDPre-IND meeting requested after year-endIND for the myocardial ischaemia-reperfusion injury programSubmission targeted before end of CY2026
Oncology expansionMay–Aug 2026Anti-tumour and cardioprotection studies with doxorubicinPhase Ib feasibility under assessment
Stroke programFY2027Prerequisite stroke model to support a Phase IIaFunded
Oral TRPC inhibitorFY2027Next-generation, orally dosed moleculeInitiation funded
Commercial dose formFY2027CMC developmentFunded
IP fortificationFY2026Composition-of-matter patent allowed; trademark grantedAchieved

ESG commitments and cost programs

No formal ESG targets or cost-reduction programs with numerical targets are disclosed. Management cites disciplined capital and cost management.

Medium-term targets and guidance

No financial guidance is given, which is standard for a pre-revenue biotech. Operational guidance:

  • Safety review after the first 8 PROTECT-MI patients: 2H CY2026

  • Last patient dosed: mid-CY2027

  • Topline results: about three months after last-patient follow-up, so Q3/Q4 CY2027

  • IND submission: before end of CY2026

  • FY2026 R&D rebate (A$1.72m): quarter ending 31 Dec 2026

Products & Services

All assets sit in the single discovery and development segment. None is marketed and no pricing exists.

Xolatryp® (formerly NYR-BI03), the lead asset

AttributeDetail
ModalitySmall molecule; intravenous infusion in PROTECT-MI. Subcutaneous dosing tested preclinically for oncology.
MechanismInhibits TRPC3, TRPC6 and TRPC7 channels to limit excessive Ca²⁺ entry into stressed cells. Mechanistic work with WRAIR/UNSW indicates mitochondrial stabilisation and reduced mitochondrial calcium loading in brain cells.
Clinical statusPhase I complete (48 healthy volunteers; all doses safe and well tolerated; no dose-limiting toxicities or serious adverse events; therapeutic exposure within 10 minutes; linear, predictable pharmacokinetics with no sex differences). Phase IIa (PROTECT-MI) recruiting since July 2026.
IPUS composition-of-matter patent allowed (Notice of Allowance, May 2026). Once the issue fee is paid, it protects the chemical structure for 20 years from the September 2024 priority date (to about September 2044, before any extension). Composition-of-matter application published. Xolatryp® trademark granted.
Target customerHospital interventional cardiology, cardio-oncology and acute neurology. Commercial counterparty: a pharma licensee.
Launch yearNot applicable (investigational)
ProgramIndicationStageKey dataNext step
Myocardial ischaemia-reperfusion injurySTEMI patients undergoing primary PCIPhase IIa (PROTECT-MI)Phase I safety; preclinical cardioprotection studies 1a, 1b and 2Safety review after first 8 patients (2H 2026); topline Q3/Q4 CY2027; US IND before end of CY2026
Myocardial ischaemia & arrhythmia controlArrhythmia incidence after MIExploratory endpoint inside PROTECT-MIListed as a company program on the websiteRead-out with PROTECT-MI
Anthracycline cardiotoxicity (cardio-oncology)Doxorubicin-induced cardiomyopathyPreclinical, completed5-week rodent study: significant protection across four cardiac-function measures, comparable to dexrazoxane (see 5.2)Phase Ib oncology/cardioprotection trial being assessed and partly funded by the Sept 2026 raise
Oncology combinationLiver cancer model with doxorubicinPreclinicalTumour-volume change at Day 14: Xolatryp alone -32%, doxorubicin alone -41%, combination -57%Feeds into Phase Ib design
Ischaemic strokeAcute neuroprotectionPreclinicalStatistically significant neuroprotection (stroke study, Feb 2024)A prerequisite stroke model, funded by the Sept 2026 raise, to support a Phase IIa stroke study
Traumatic brain injurySecondary brain injury after TBIPreclinicalSignificant neuroprotection (Apr 2025); reduced mitochondrial Ca²⁺ loading (WRAIR/UNSW)No funded clinical step disclosed

Indication-by-indication catalog

Cardiomyopathy study detail (21 August 2026 release)

ArmChange vs baseline (%)
Doxorubicin alone-46.0
Doxorubicin + Xolatryp-30.3
Doxorubicin + dexrazoxane (the approved cardioprotectant)-32.6

One cardiac-function parameter was reported by secondary coverage as follows. The specific parameter, likely an ejection or shortening measure, is not named in the secondary source.

Xolatryp versus doxorubicin gave p<0.0001 on that measure. Structural and histopathological findings supported the functional results. The company explicitly said the study was not designed or powered to show superiority to dexrazoxane, and that preclinical results may not translate to humans.

Pipeline extensions (pre-candidate)

AssetDescriptionStatus
Next-generation oral TRPC inhibitorOrally dosed TRPC inhibitor for chronic or outpatient indicationsInitiation funded by the Sept 2026 raise
Xolatryp commercial dose formCMC work toward a commercial formulationFunded by the Sept 2026 raise

Legacy or deprioritised programs (disclosed at IPO and in 2021)

ProgramDescriptionCurrent status
Oral PCSK9 inhibitor (from the Cardio Therapeutics acquisition)Oral small molecule to lower LDL-cholesterol in patients who respond poorly to or cannot take statinsNot in current pipeline disclosures.
NYX-1010 (brain injury, IV/intranasal)Earlier brain-injury compound named in 2021 coverageSuperseded by NYR-BI03/Xolatryp
Peripheral nerve pain; autoimmune (e.g. psoriasis)Early discovery programs listed by data aggregatorsNot in current disclosures

Financial Narrative

Important framing: Nyrada is pre-revenue. Revenue, gross profit and EBITDA-based margins, revenue CAGR, ROIC, interest coverage, asset turnover and the cash conversion cycle are therefore not meaningful. They are listed below and left blank. "Income" means other income, chiefly the R&D tax incentive and interest.

Income statement

Sources: Stockopedia income statement (FY2022–FY2025, from annual reports under Australian Accounting Standards); FY2025 Preliminary Final Report (income A$2,558,803; loss A$4,845,671); FY2026 Full Year Results (loss A$6.56m). FY2021 for reference: income A$2.34m, opex A$5.87m, net loss A$3.54m (Stockopedia).

Margins: Gross, operating, EBITDA and net margins are not meaningful with no product revenue. Revenue CAGR is not meaningful.

Half-year reference points: In H1 FY2025 (6 months to 31 Dec 2024) the loss was A$2.457m, versus a profit of about A$0.14m in H1 FY2024. H1 FY2025 R&D expenditure was A$1.81m and corporate/administration A$0.48m (Half Year Report to 31 Dec 2024).

Balance sheet

Sources: FY2024 cash A$4,769,374 (Half Year Report Dec 2024); FY2025 cash A$2.93m and FY2026 cash A$8.38m (FY2026 Full Year Results; the June 2026 Appendix 4C reports A$8.39m, a A$0.01m rounding discrepancy). Simply Wall St (Oct 2026) reports short-term assets of about A$10.4m exceeding liabilities, and no debt. Zero debt for FY2024–FY2025 is inferred from the absence of borrowings in disclosures and the 2021 repayment of the Noxopharm loan.

Interim cash track (AUD M)

Sources: Quarterly Activities Reports and Appendix 4C; Half Year Report Dec 2024.

Cash flow

FY2026 = August 2025 placement of A$8.25m, plus unquantified proceeds from option exercises.

Quarterly operating cash burn: about A$1.84m (Sep-2024 quarter), A$1.05m (Jun-2024 quarter), A$1.75m (Dec-2025 quarter) and A$0.51m (Mar-2026 quarter, reported net of R&D rebate timing effects). A full June 2026 quarter figure was not captured.

R&D tax incentive receipts and accruals (AUD M)

Sources: 1Q FY2025 4C (FY2024 claim re-estimated at A$1.38m; A$1.24m received in H1 FY2025 per Half Year Report); R&D rebate release of 29 May 2026 (A$2,454,848 received for FY2025; earlier estimate A$2.16m); FY2026 results (A$1.72m accrued). The FY2026 release says this will be received in the quarter ending 31 December 2026 in one place and "2025" in another. The latter is an evident typographical error.

Ratios

ROIC, net debt/EBITDA, interest coverage, asset turnover and the cash conversion cycle are not meaningful for a debt-free, pre-revenue developer. ROE and ROA are deeply negative in every year because there are recurring losses and no revenue.

Commentary on trends, inflections and drivers

FY2022–FY2023, a discovery-stage peak: With two parallel programs (PCSK9 and brain injury) running after the A$11m March 2021 raise, operating expenses peaked at A$9.36m in FY2023 and the loss at A$7.78m. The FY2023 Annual Report described a difficult capital-markets year.

FY2024, a trough in spend: Opex fell to A$4.79m and the loss narrowed to A$1.39m. Spending was reprioritised to a single TRPC asset, and income of A$3.40m (R&D incentive plus other items) was relatively high. The A$0.075 placement in March 2024 marks the low point in the company's cost of capital.

FY2025, the clinical transition: GLP toxicology, manufacturing and the start of Phase I pushed opex to A$7.40m and the loss to A$4.85m. Cash ended the year at only A$2.93m, about one to two quarters of runway, before the A$8.25m August 2025 placement. That placement was the key financing inflection.

FY2026, Phase IIa preparation: The loss widened to A$6.56m as the company finished Phase I, prepared Phase IIa (HREC approval, site start-up, drug supply) and ran oncology studies. Cash still rose to A$8.38m. The A$8.25m placement, the A$2.45m R&D rebate and option-exercise proceeds outweighed the spend.

FY2027 setup: The September 2026 placement (A$12.0m) plus cash and the expected R&D rebate takes stated available funding to about A$22.1m before the SPP, with A$15.8m earmarked for clinical development. Up to A$5.125m of this depends on holder approval of director participation, expected around February 2027. With a quarterly burn likely to rise as PROTECT-MI recruits, management states that the raise funds the trial through topline data.

Indicative analyst derivation (not a disclosed figure): Australia's refundable R&D tax offset for entities with turnover under A$20m is generally 43.5% of eligible spend. On that basis, the rebates imply eligible R&D spend of roughly A$3.2m (FY2024), A$5.6m (FY2025) and A$4.0m (FY2026). The FY2026 figure is lower because some overseas or ineligible costs may be excluded, and because Phase IIa patient costs mostly fall in FY2027. Treat these as indications only.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / programs

Drug discovery & development (sole segment)

TRPC ion-channel inhibitor platform

Xolatryp® (IV), next-generation oral TRPC inhibitor (discovery), commercial dose-form development

Results by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Segment income (AUD Mn, other income incl. R&D incentive)

3.402.56—

Segment result: loss after tax (AUD Mn)

-1.39-4.85-6.56

Share of group income (%)

100100100

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

Total income incl. R&D incentive (AUD Mn)

1.111.583.402.56—

Total operating expenses (AUD Mn)

5.079.364.797.40—

Operating profit / loss (AUD Mn)

-3.96-7.78-1.39-4.85—

Pre-tax profit / loss (AUD Mn)

-3.96-7.78-1.39-4.85—

Net profit / loss after tax (AUD Mn)

-3.96-7.78-1.39-4.85-6.56

Dividends per share (AUD)

00000

Key Financials

MetricFY2024FY2025FY2026

Cash and equivalents (AUD Mn)

4.772.938.38

Total debt (AUD Mn)

000

Net debt (AUD Mn)

-4.77-2.93-8.38

Key Financials (Sep-2024–Jun-2026)

MetricSep-2024Dec-2024Sep-2025Dec-2025Mar-2026Jun-2026

Cash balance (AUD Mn)

2.985.717.927.126.748.39

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Equity raised, gross (AUD Mn)

———3.368.25

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Key Financials (FY2024 claim–FY2026 claim)

MetricFY2024 claimFY2025 claimFY2026 claim

Rebate (received, or accrued for FY2026) (AUD Mn)

1.382.451.72

Financial Analysis

MetricFY2022FY2023FY2024FY2025FY2026

Debt to equity (x)

00000

Results by Region

RegionFY2024FY2025FY2026

Australia: total income (AUD Mn)

3.402.56—

Americas: income (AUD Mn)

000

EMEA: income (AUD Mn)

000

Other APAC: income (AUD Mn)

000

Share Price History

DatePriceContextSource

16 Jan 2020

0.20

IPO price

Stockhead

Mar 2021

0.26

Placement price

Biotech Dispatch

Mar 2024

0.075

Placement price (approximate cycle low)

Placement release

Aug 2025

0.30

Placement price

FY2026 results

8 Jan 2026

~1.40

At HREC approval; near 52-week high (~1.435)

InvestSMART

19–20 Mar 2026

~0.51–0.54

At PROTECT-MI commencement announcement

InvestSMART

Jun 2026

~0.42–0.45

Near the post-peak trough

InvestSMART

6 Aug 2026

0.68—

InvestSMART

Aug/Sep 2026

0.75

Stockopedia close; implied market cap A$181.2m

Stockopedia

~21 Sep 2026

0.62

Placement price; 15.1% discount to last traded (implying about A$0.73)

Small Caps

Valuation Snapshot

MetricValueSource / note

1-year return

About +176%

Stockopedia (snapshot Aug/Sep 2026); outperformed the All Ordinaries by about 176 percentage points

3-year return

Price was A$0.075 in Mar 2024 against roughly A$0.5–0.75 in late 2026, implying a multi-bagger, but no exact 3-year base date is available.

—

5-year return

The Mar 2021 placement was at A$0.26.

—

Since IPO (A$0.20)

Positive; StoxRay showed +131% at A$0.52 (May 2026)

StoxRay

Valuation Snapshot by Multiple

MultipleValue

P/E

Not meaningful (loss-making)

EV/Sales

Not meaningful (no revenue)

Market cap

A$130.0m (Simply Wall St, Oct 2026) vs A$181.2m (Stockopedia, Aug/Sep 2026). The gap reflects price moves and possibly differing share counts after the September 2026 issue.

Enterprise value (indicative)

Market cap less about A$20m of cash and receivables after the September placement (subject to settlement), giving an EV of roughly A$110–160m

Capital Markets

ItemStatus

Dividend history and policy

No dividends ever paid; none expected

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No debt

Analyst Conclusions

Management guidance (operational)

ItemTiming
PROTECT-MI safety review (first 8 patients)2H CY2026
US FDA IND submissionBefore end of CY2026 (pre-IND meeting requested)
FY2026 R&D rebate (A$1.72m)Quarter ending 31 Dec 2026
Director placement approval general meeting~Feb 2027
PROTECT-MI last patient dosedMid-CY2027
PROTECT-MI primary completion (ClinicalTrials.gov)30 Jun 2027 (estimated)
PROTECT-MI topline dataQ3/Q4 CY2027
Study completion (ClinicalTrials.gov)30 Sep 2027 (estimated)

Consensus growth expectations: Not meaningful or not available for a pre-revenue company. Stockopedia shows FY2026E and FY2027E columns, but the values were not captured.

Bull case

  1. A de-risked molecule entering a no-competitor niche. Clean Phase I safety, under-10-minute exposure and a 100-patient randomised Phase IIa give Nyrada the first credible TRPC readout in STEMI, an indication with no approved therapy. A positive efficacy signal on infarct extent or troponin I would be highly differentiated.

  2. Dual-value cardio-oncology optionality. Preclinical data show cardioprotection comparable to the only approved agent (dexrazoxane) and anti-tumour additivity (-57% tumour volume for the combination vs -41% for doxorubicin alone). That supports a second, potentially faster Phase Ib-to-partnering pathway.

  3. Funded, aligned and IP-protected. About A$22m of funding sources, US composition-of-matter protection to about 2044, and a transaction-savvy board that is putting in A$5.1m of its own money set up a licensing event after 2H CY2027 data without an interim forced raise.

Bear case

  1. History is against cardioprotection. Cyclosporine, elamipretide and conditioning all failed in STEMI despite strong preclinical data. PROTECT-MI's primary endpoint is safety, so even a "successful" trial may give an efficacy signal too weak to secure a partner.

  2. Execution and timeline risk. First dosing came about three months later than guided, only three of at least nine planned sites were active by September 2026, and STEMI recruitment depends on emergency workflows. Further slippage would push topline into 2028 and raise cash burn.

  3. Valuation and dilution. A market cap of about A$130–180m for a single preclinical-to-Phase IIa asset with no revenue prices in substantial success. Attaching and piggyback options (A$0.93 and A$1.40) and serial raises imply continued dilution. The share price has already fallen from about A$1.40 (January 2026) to the A$0.40s within the past year, showing how sensitive the stock is to sentiment.

Key catalysts and monitorables (next 12 months)

CatalystExpected timingWhy it matters
Sep-2026 quarter 4CLate Oct 2026Cash after placement; burn rate; recruitment numbers
SPP resultQ4 CY2026Retail demand; up to A$2.0m
Safety Review Committee (first 8 patients)2H CY2026First patient-level safety signal
Pre-IND meeting and IND submissionBy Dec 2026US regulatory validation; opens US sites
FY2026 R&D rebate receiptQ4 CY2026A$1.72m of non-dilutive cash
Site activations (AU/NZ)RollingLeading indicator for the mid-2027 last-patient target
General meeting on director participation~Feb 2027A$5.125m of funding contingency
Phase Ib oncology design decision1H CY2027Second clinical indication
Stroke prerequisite model dataCY2027Neurology pathway
Interim report17 Feb 2027H1 FY2027 financials

Analyst verdict

Nyrada is now a different company from the two-program discovery shell that listed in January 2020. Over the past 18 months it has executed the hardest transition for a micro-cap biotech, from preclinical to patient-stage. It completed a clean 48-subject Phase I, won ethics approval, activated sites, and dosed the first STEMI patient in a randomised, placebo-controlled Phase IIa. It did this while securing US composition-of-matter protection to the mid-2040s and adding a second scientific story in cardio-oncology. In that model, preclinical cardioprotection matched dexrazoxane and tumour responses improved. The September 2026 raise of A$12.0m at A$0.62, more than double the August 2025 price, removes near-term funding risk through topline. The board's A$5.125m commitment is unusually strong alignment for a company of this size.

The investment case is still binary and back-end loaded. Value creation depends almost entirely on PROTECT-MI efficacy signals due in 2H CY2027, in an indication that has humbled many better-funded programs. Because the trial is safety-primary, investors and potential licensees will look closely at secondary measures such as infarct extent, troponin I and cardiac function. A 100-patient study may not power those convincingly. Execution risk is already visible: first dosing slipped three months, and the site network is still being built.

On balance, Nyrada is a well-governed, adequately funded, high-risk, high-optionality single-asset developer. The near-term risk-reward depends on milestones: the first-8-patient safety review, IND submission and recruitment cadence over the next two quarters will determine whether the CY2027 readout timetable is credible. For institutional investors, the position is best sized as a venture-style option on a first-in-class TRPC platform. Recruitment metrics in each Appendix 4C are the most important leading indicator to monitor.


Prepared from publicly available information as at 12 October 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducation

James Bonnar

Managing Director & CEO

Joined Feb 2018; Board MD since 8 Oct 2025

11 years at Neuren Pharmaceuticals as Director, CMC & Regulatory Affairs, then Director, Clinical Operations, overseeing development in TBI and neurodevelopmental disorders. Earlier roles in diabetes research, GMP manufacturing and formulation. Over 20 years in life sciences.

BSc (Chemistry); MRQA

Dr Benny Evison

Chief Scientific Officer

Among Nyrada's first scientists

Postdoctoral fellow at St Jude Children's Research Hospital, Memphis (DNA-repair targeting to enhance chemotherapy). PhD work on the mechanism of pixantrone.

BSc (Med Sci) (Hons), PhD, La Trobe University

David Franks

Company Secretary

—

Automic Group

—

Board of Directors

NameRoleIndependence (analyst view)Background

John Moore

Non-Executive Chair

Independent non-executive

CEO of Acorn Energy (2006–2015): acquired CoaLogix for US$11m and later sold it for US$101m; took Comverge public. Partner and CEO of Edson Moore Healthcare Ventures (2002), which acquired 16 drug-delivery investments from Elan for US$148m. Chair of Scientific Industries (OTCQB: SCND) and Trialogics; director of Phase Holographic Imaging and Cormetech. Rutgers University.

James Bonnar

Managing Director & CEO

Executive

See above

Christopher Cox

Non-Executive Director

Non-executive

Co-founder and General Partner of Population Health Partners (since Apr 2020). Former EVP & Chief Corporate Development Officer of The Medicines Company (2016–2019). Former partner and Chair of the Corporate Department at Cadwalader, Wickersham & Taft. Boards: Scientific Industries, Niroda Therapeutics, Civia Health.

Marcus Frampton

Non-Executive Director

Non-executive

Chief Investment Officer of the Alaska Permanent Fund Corporation (about US$85bn sovereign wealth fund). Previously at Lehman Brothers, PCG Capital Partners and LPL Financial.

Dr Rüdiger Weseloh

Non-Executive Director

Independent non-executive

Executive Director, Business Development at EMD Serono (Merck KGaA), with over 80 transactions across 19 years. Former biotech equity analyst. Max Planck postdoctoral researcher.

Dr Ian Dixon

Non-Executive Director

Non-executive; founder-vendor of Cardio Therapeutics

Co-founder of Cynata (ASX: CYP), Cardio Therapeutics and Exopharm (ASX: EX1). PhD in biomedical engineering (Monash), MBA (Swinburne).

Board & Management Changes

DateChangeContext

8 Oct 2025

James Bonnar appointed Managing Director

Executive representation on the Board ahead of Phase IIa

Nov 2025

Gisela Mautner retired

Followed Noxopharm's full exit from the register in May 2025

Major Shareholders

HolderStakeComment

Board and management (aggregate)

Not precisely disclosed; material

Bought about 26% of Noxopharm's exited parcel (May 2025). Board committed A$5.125m to the Sept 2026 placement (subject to approval).

Noxopharm Limited

0%

Held 30.51% at IPO, then 18.60%, then 5.13%, then fully exited in 2025

Substantial holders

Not captured

—

Competitive Landscape

Competitors by Segment

IndicationCompetitor / productOwnerMechanismStage / status (as last known)

STEMI reperfusion injury

FDY-5301 (IV sodium iodide)

Faraday Pharmaceuticals (private, US)

Reductive antioxidant

Late-stage (IOCYTE AMI program); current status should be verified

STEMI reperfusion injury

Elamipretide

Stealth BioTherapeutics (US)

Mitochondria-targeted peptide

Failed in STEMI (EMBRACE STEMI); pivoted to other indications

STEMI reperfusion injury

Cyclosporine (mPTP inhibition)

Generic

Mitochondrial permeability transition pore

Failed in Phase III (CIRCUS, CYCLE)

STEMI reperfusion injury

Remote ischaemic conditioning (device/procedure)

Various

Conditioning

Neutral in CONDI-2/ERIC-PPCI

Anthracycline cardiotoxicity

Dexrazoxane (Zinecard; Totect/Savene)

Pfizer; Clinigen (and generics)

Iron chelation / topoisomerase IIβ

Approved; the only approved cardioprotectant; use restricted by label and tumour-protection concerns

Anthracycline cardiotoxicity

Repurposed cardiology drugs (ACE inhibitors, beta-blockers, statins)

Generic

Neurohormonal

Off-label; mixed evidence

Ischaemic stroke neuroprotection

Nerinetide

NoNO Inc. (private, Canada)

PSD-95 inhibitor

Phase III (ESCAPE-NA1, FRONTIER); mixed results

Ischaemic stroke neuroprotection

ARG-007

Argenica Therapeutics (ASX: AGN)

Cationic arginine-rich peptide

Phase II; direct ASX peer

Ischaemic stroke / TBI

Glibenclamide IV (BIIB093)

Biogen

SUR1-TRPM4 inhibitor

Large hemispheric infarction program discontinued

TRPC6 inhibition (other indications)

BI 764198

Boehringer Ingelheim

TRPC6 inhibitor

Phase II (FSGS); validates TRPC6 as a druggable target

TRPC5 inhibition

GFB-887

Goldfinch Bio (wound down 2023)

TRPC5 inhibitor

Discontinued

Cardio-renal / heart failure (ASX peer)

VB0004 / VB0395

Vectus Biosystems (ASX: VBS)

Anti-fibrotic

Early clinical

Peer Comparison FY2026

MetricNyrada (NYR)Noxopharm (NOX)

Lead stage

Phase IIa (STEMI)

Preclinical / early clinical

Latest annual net loss

A$6.56m (FY2026)

—

Cash (latest)

A$8.38m (Jun-2026), before the A$12m Sept-2026 raise

—

R&D intensity

Majority of opex (H1 FY2025: about 79% of opex)

—

Market cap

About A$130–181m (sources conflict, Aug–Oct 2026)

About A$20m (TipRanks, 2025)

Recent Developments

--

Company Snapshot

2017

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean human safety data. Phase I in 48 healthy volunteers showed no serious adverse events and no dose-limiting toxicities, with linear pharmacokinetics (FY2026 results; Small Caps, Sept 2026).
  • Rapid onset suits the PCI window. Therapeutic exposure was achieved within 10 minutes (Small Caps, Sept 2026).
  • Long-dated IP. The US composition-of-matter Notice of Allowance (May 2026) gives a 20-year term from the September 2024 priority date.
  • Funded to topline. Cash was A$8.38m at 30 June 2026 plus A$12.0m raised in September 2026, giving about A$22.1m of stated funding sources before the SPP and A$15.8m earmarked for clinical work.
  • Strong preclinical breadth. There is significant protection in TBI (Apr 2025), stroke (Feb 2024), myocardial ischaemia (2024) and doxorubicin cardiomyopathy. In the cardiomyopathy model, the decline was -30.3% with Xolatryp versus -46.0% with doxorubicin alone and -32.6% with dexrazoxane, with p<0.0001 versus doxorubicin (21 Aug 2026).
  • Insider alignment. The board and management bought about 26% of Noxopharm's exited stake (2025) and committed A$5.125m to the September 2026 placement.

Weaknesses

  • Single-asset dependency. Every program is Xolatryp, apart from an oral successor that is still at discovery stage.
  • No revenue, widening losses. The loss grew from A$1.39m (FY2024) to A$4.85m (FY2025) to A$6.56m (FY2026).
  • Safety-primary Phase IIa. Efficacy measures (infarct extent, troponin I, cardiac function, arrhythmias) are secondary or exploratory.
  • Timeline slippage. First dosing was guided for April 2026 (19 Mar 2026 release) but happened in July 2026.
  • Thin disclosed organisation. Only two named senior managers, with heavy reliance on outsourcing.
  • History of low-priced dilution. Placements were done at A$0.075 (Mar 2024) and A$0.30 (Aug 2025). The September 2026 placement adds attaching and piggyback options, which create future overhang.

Opportunities

  • US IND before end of CY2026 opens US sites and a US partnering narrative.
  • Cardio-oncology Phase Ib builds on dexrazoxane-comparable preclinical efficacy, plus tumour-volume reduction of -57% for the combination versus -41% for doxorubicin alone.
  • Stroke Phase IIa pathway has a prerequisite model funded from the September 2026 raise.
  • An oral TRPC inhibitor could open chronic indications such as heart failure or renal disease. Boehringer's clinical TRPC6 work validates the target class.
  • Licensing after Phase IIa. The board has transaction experience (Weseloh: over 80 deals at Merck KGaA; Cox: former Chief Corporate Development Officer of The Medicines Company).
  • Non-dilutive funding. A$1.72m of R&D rebate is accrued for FY2026, and the rebate will grow with PROTECT-MI spend.

Threats

  • Class failure risk. Cyclosporine (CIRCUS), elamipretide (EMBRACE STEMI) and conditioning approaches all failed to improve outcomes in STEMI.
  • Funding contingency. A$5.125m of the September 2026 placement depends on holder approval around February 2027.
  • Recruitment risk. Sites depend on emergency STEMI throughput. Only three sites were active by September 2026, against at least nine planned.
  • Share-price volatility. The 52-week range was about A$0.225 to A$1.435. An ASX price query followed a 30% intraday move (15 Jul 2026).
  • Competing reperfusion programs (for example Faraday's FDY-5301) could set the regulatory or partnering bar higher.
  • Translational risk. The company itself warns that preclinical results may not translate to humans (21 Aug 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Significant neuroprotection in a preclinical TBI studySupports the neurology optionality
9 Apr 2025Phase I dosing update #1On-schedule progression
15 Apr 2025Mar-2025 quarter 4CRoutine
2 May 2025Phase I dosing update #2; advance to third cohortDose escalation proceeding safely
May 2025Noxopharm reduces its stake from 18.60% to 5.13%, then exits fully (about A$2.5m); about 26% bought by Nyrada board and managementOverhang removed; insider alignment rises
14 Jul 2025Final Phase I cohort to commencePhase I near completion
23 Jul 2025Xolatryp Phase IIa in cardioprotection advancedCardiology chosen as the lead indication
31 Jul 2025Jun-2025 quarter 4CCash low (A$2.93m at 30 June)
4 Aug 2025A$8.25m placement at A$0.30Financing inflection
6 Aug 2025Positive final review of Phase IDe-risks safety
22 Aug 2025FY2025 Preliminary Final Report: loss A$4.85mAudited, unmodified opinion
16 Sep 2025Mitochondrial stabilisation mechanism dataMechanistic validation
29 Sep 2025"Xolatryp Achieves Key Clinical Milestone"Associated with full unblinded Phase I results
8 Oct 2025James Bonnar appointed Managing DirectorGovernance
21 Oct 2025Sep-2025 quarter 4C: cash A$7.92mRoutine
Nov 2025AGM; Gisela Mautner retiresLast Noxopharm link removed
10–18 Dec 2025Chair buys 1.2m CDIs at A$0.20 (as reported); Dixon sells 600,000 at A$0.646Mixed insider signals
Dec 2025 – Jan 2026Multiple quotations of securities and cleansing statements (option exercises)Non-dilutive-to-price capital inflow
8 Jan 2026HREC approval for Phase IIaKey regulatory step; shares around A$1.40, near the 52-week high
23 Jan 2026Dec-2025 quarter 4C: cash A$7.12m; R&D rebate A$2.16m expectedRoutine
28–29 Jan 2026Investor webinar; substantial holder updateIR activity
5 Feb 2026Phase IIa clinical trial factsheetTrial design disclosure
18 Feb 2026Half-year FY2026 resultsRoutine
19 Mar 2026PROTECT-MI to commence; first dosing guided for April 2026First dosing later slipped to July
20 Mar 2026ASX SMIDCaps conference presentationIR
22 Apr 2026First PROTECT-MI site activated (Nepean)Recruitment opens
19 May 2026US composition-of-matter Notice of Allowance; trading halt and ASX pauseMajor IP de-risking
20 May 2026Xolatryp enhances anthracycline anti-tumour efficacy (preclinical)Oncology optionality
29 May 2026A$2.455m R&D rebate received for FY2025Non-dilutive cash, above the A$2.16m estimate
3 Jun 2026Cardioprotection pilot study completeSets up the powered study
16 Jun 2026PROTECT-MI update: on track for CY2027 completionTimeline reaffirmed
2–6 Jul 2026First patient dosed in PROTECT-MICompany becomes a patient-stage developer
15 Jul 2026ASX price query after shares rose from A$0.41 to A$0.535 intraday; company says it knows of no unannounced informationVolatility
27 Jul 2026Jun-2026 quarter 4C: cash A$8.39mRoutine
18 Aug 2026FY2026 results and Annual Report: loss A$6.56m; pre-IND meeting requestedFinancial close-out
21 Aug 2026Powered cardiomyopathy study: significant cardioprotection, comparable to dexrazoxaneStrongest oncology-adjacent data to date
~21 Sep 2026A$12.0m placement at A$0.62 plus A$2.0m SPP; board A$5.125mFunds PROTECT-MI to topline
5 Oct 2026ClinicalTrials.gov record updated; status "Recruiting"Ongoing enrolment

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (%): Share of group income held from 100% in FY2024 to 100% in FY2026.
Nyrada Inc. — Revenue by Segment (%)
Series (%)FY2024FY2025FY2026
Share of group income100100100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.